C
큐라클
365270KOSDAQ43.5 / 100
Reference Date: 2026-10-23
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Curacle is a biotech venture company developing innovative therapeutics targeting endothelial dysfunction, leveraging its proprietary platforms Solvadys and Eagles to advance first-in-class drug candidates such as CU06, CU71, and CU01. CU06, a retinal disease treatment, demonstrated vision improvement in Phase 2a trials, while collaborations with MapTics have expanded its antibody-based pipeline.
Number of Employees
31people
Average Salary
81.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
5.46Industry Average 1.200.0Point
4.5x industry avg (risky)
ROE
-54.03Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
9.08Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼91.9% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼25.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -40.6% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (30%)
Current 9,140Won52-week high 19,71052-week low 4,565
1-month return3.0Point
1m -0.65% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0